**SECOND-QUARTER 2024 RESULTS**

**TOTAL COMPANY**

$10.4B

+9.3%\(^1\)

SALES WORLDWIDE

$1.14\(^2\)

ADJUSTED DILUTED EPS

**BUSINESS HIGHLIGHTS**

**BREAKTHROUGH INNOVATION IN PERIPHERAL ARTERY DISEASE**

- FDA approval of the Esprit™ below-the-knee (BTK) system.
- System is designed to keep arteries open and deliver a drug to support vessel healing prior to completely dissolving.

**EXPANDING IN BIOWEARABLES**

- FDA clearance for two new over-the-counter continuous glucose monitoring systems: Lingo™ and Libre Rio™.
- Systems are based on Abbott’s world-leading FreeStyle Libre™ continuous glucose monitoring technology.

**RAISED FULL-YEAR GUIDANCE**

$4.61 to $4.71\(^*\)

ADJUSTED DILUTED EPS

9.5% to 10.0%\(^5\)

ORGANIC SALES GROWTH

Excluding COVID-19 testing-related sales

**KEY BUSINESS UNITS**\(^3\)

**MEDICAL DEVICES** 12.1%

**DIAGNOSTICS** 5.9%

**PHARMACEUTICALS** 8.1%

**NUTRITION** 7.5%

---

\(^1\) Organic sales growth excludes impact of foreign exchange, the impact of discontinuing the ZonePerfect® product line in the Nutrition business, and the impact of the acquisition of Cardiovascular Systems, Inc. during the first year post-acquisition. For full financial data and reconciliation of non-GAAP measures, please see our press release dated July 18, 2024, available at www.abbottinvestor.com.

\(^2\) Includes the impact of COVID-19 testing sales.

\(^3\) Includes the impact of COVID-19 testing sales.

\(^4\) Excludes the impact of COVID-19 testing sales.

\(^5\) Excludes the impact of COVID-19 testing sales.

---

**FORWARD-LOOKING STATEMENTS**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.